Abu Dhabi fund ADQ acquires Swiss Acino

Abu Dhabi fund ADQ has entered a definitive agreement to acquire Swiss pharmaceutical company Acino. This marks ADQ’s largest deal yet in the healthcare and pharmaceuticals portfolio.

ADQ will acquire 100 per cent of Acino from its current stakeholders, which include Nordic Capital and Avista Capital Partners. With this acquisition, the Abu Dhabi fund intends to create an integrated pharma platform with formulation development, in-licensing, manufacturing capabilities in key markets.

Ensuring high quality

“Our aim for ADQ’s healthcare and pharma cluster is to ensure access to affordable, essential medicines and advance new, innovative treatments that help improve people’s lives,” said Fahad Al Qassim, Executive Director, Healthcare & Pharma at ADQ. “Acino will enable ADQ to deliver an even greater level of growth, innovation and ambition across the pharma value chain.”

“Acino is committed to advancing the development of healthcare by enhancing access to high-quality medicines and ADQ’s support will accelerate this ambition,” said Steffen Saltofte, CEO of Acino.